Pure Global AI
NCT06005155Completed

Lithium Versus Anticonvulsants and the Risk of Physical Disorders

Lithium Versus Anticonvulsants and the Risk of Physical Disorders - Results From a Comprehensive Long-term Nation-wide Population-based Study Emulating a Randomised Trial
Mental Health Services in the Capital Region, DenmarkClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Bipolar Disorder
Drug/Device/Intervention
Lithium
Study type
Observational
Intervention type
drug
Sponsor & location
Primary sponsor
Mental Health Services in the Capital Region, Denmark
Location
Copenhagen, Denmark
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2022
End date
Jul 01, 2023
Enrollment
169285 participants
Primary outcome

Incident stroke (separately for intracerebral hemorrhage and cerebral infarction),Arteriosclerosis,Angina pectoris,Myocardial infarction,Diabetes mellitus (separately for type 1 diabetes and type 2 diabetes),Myxoedema,Osteoporosis,Dementia (separately for Alzheimer's disease and other dementia),Parkinson's disease,Chronic kidney disease (definite chronic kidney disease and possible Chronic kidney disease)

Summary

Nationwide population-based register linkage study covering the entire 5.9 million
 inhabitants in Denmark systematically investigating the associations between sustained
 long-term use of lithium versus lamotrigine and valproate, and the risk of a range of
 physical disorders emulating a randomized trial.

ICD-10 classifications
Bipolar affective disorderBipolar affective disorder, unspecifiedOther bipolar affective disordersBipolar affective disorder, currently in remissionBipolar affective disorder, current episode mixed
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06005155
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06005155 through Pure Global AI's free database. This phase not specified trial is sponsored by Mental Health Services in the Capital Region, Denmark and is currently Completed. The study focuses on Bipolar Disorder. Target enrollment is 169285 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.